Reuters logo
BRIEF-Cytrx reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas
2016年11月29日 / 上午11点17分 / 10 个月前

BRIEF-Cytrx reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

Nov 29 (Reuters) - Cytrx Corp :

* Cytrx-Reports statistically significant updated results from pivotal phase 3 trial of aldoxorubicin in patients with second-line soft tissue sarcomas

* Cytrx Corp - aldoxorubicin also achieves primary endpoint of statistically significant improvement

* Cytrx Corp - cytrx plans to file an nda with u.s. Fda in 2017

* Cytrx- aldoxorubicin achieves primary endpoint of statistically significant improvement in progression-free survival in patients with leiomyosarcoma

* Cytrx Corp-aldoxorubicin achieves primary endpoint of statistically significant improvement in progression-free survival in patients with liposarcoma Source text - bit.ly/2fHfDZ1 Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below